Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Study sponsor: Evommune, Inc. · EVMN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-07-27Actual
Enrollment · participants119Actual
Source updated2025-03-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.